Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04712734 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
A Phase 1 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04712734 is a Phase 1 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT04712734, a Phase 1 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
Interventions
- DRUG Iloperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04712734
The ClinicalTrials.gov registry entry for NCT04712734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iloperidone is the first listed.
NCT04712734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04712734 about?
NCT04712734 is a clinical study titled "A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia". This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
What is the current status of trial NCT04712734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-01-13. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT04712734?
The interventions under investigation include: Iloperidone (DRUG).
Who is sponsoring clinical trial NCT04712734?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.